NZ720331A - Solid pharmaceutical compositions containing an integrase inhibitor - Google Patents

Solid pharmaceutical compositions containing an integrase inhibitor

Info

Publication number
NZ720331A
NZ720331A NZ720331A NZ72033110A NZ720331A NZ 720331 A NZ720331 A NZ 720331A NZ 720331 A NZ720331 A NZ 720331A NZ 72033110 A NZ72033110 A NZ 72033110A NZ 720331 A NZ720331 A NZ 720331A
Authority
NZ
New Zealand
Prior art keywords
superdisintegrant
iii
raltegravir
tablets
optionally
Prior art date
Application number
NZ720331A
Inventor
Decheng Ma
Sutthilug Sotthivirat
Feng Li
Majid Mahjour
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NZ720331A publication Critical patent/NZ720331A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a compressed tablet for oral administration, which comprises: (A) an intragranular component comprising: (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising: (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant; with the proviso that the tablet is free of atazanavir or a pharmaceutically acceptable salt thereof. Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. Raltegravir is also known as N-(2-(4-(4-fluorobenzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl).
NZ720331A 2009-10-26 2010-10-21 Solid pharmaceutical compositions containing an integrase inhibitor NZ720331A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25486909P 2009-10-26 2009-10-26
NZ70146510 2010-10-21

Publications (1)

Publication Number Publication Date
NZ720331A true NZ720331A (en) 2017-12-22

Family

ID=60669066

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ720331A NZ720331A (en) 2009-10-26 2010-10-21 Solid pharmaceutical compositions containing an integrase inhibitor

Country Status (1)

Country Link
NZ (1) NZ720331A (en)

Similar Documents

Publication Publication Date Title
MY162494A (en) Solid pharmaceutical compositions containing an integrase inhibitor
EP4643882A3 (en) Capsid inhibitors for the prevention of hiv
WO2005086700A3 (en) Hiv integrase inhibitors
WO2015120110A3 (en) Novel pharmaceutical formulations
MX2009006285A (en) Non-nucleoside reverse transcriptase inhibitors.
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
NZ602670A (en) Non-nucleoside reverse transcriptase inhibitors
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
WO2010042391A3 (en) Hiv integrase inhibitors
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
EP2033954A4 (en) 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
MY208261A (en) Oral pharmaceutical composition
WO2009042094A3 (en) Hiv protease inhibitors
WO2005110414A3 (en) Hiv integrase inhibitors
JO3587B1 (en) Oral dosage forms of bendamustine
WO2007050510A3 (en) Hiv integrase inhibitors
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
AU2006299042A8 (en) HIV integrase inhibitors
NZ720331A (en) Solid pharmaceutical compositions containing an integrase inhibitor
WO2023096615A3 (en) A compressed solid oral dosage form comprising pinaverium and medazepam
MX2021004553A (en) Pharmaceutical compositions and methods of making on demand solid dosage formulations.
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 21 OCT 2020 BY AJ PARK

Effective date: 20180626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2021 BY THOMSON REUTERS

Effective date: 20200926

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2022 BY THOMSON REUTERS

Effective date: 20210902

ASS Change of ownership

Owner name: MERCK SHARP + DOHME LLC, US

Effective date: 20220922

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2023 BY THOMSON REUTERS

Effective date: 20220902

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2024 BY THOMSON REUTERS

Effective date: 20230904

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2025 BY THOMSON REUTERS

Effective date: 20240903

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2026 BY THOMSON REUTERS

Effective date: 20250901